On Wednesday, Shares of Transocean LTD (NYSE:RIG), lost -0.75% to $14.48.
Transocean Ltd., declared its intent to delist its shares from the SIX Swiss Exchange (SIX). The company anticipates the SIX listing authorities to approve its delisting application priority to year-end and the related delisting to occur in the first quarter of 2016.
The company will remain incorporated in Switzerland and its shares will continue to be listed and traded on the New York Stock Exchange (NYSE).
Transocean Ltd., together with its auxiliaries, provides offshore contract drilling services for oil and gas wells worldwide. The company primarily offers deepwater and harsh environment drilling services.
Shares of Skechers USA Inc (NYSE:SKX), declined -0.27% to $30.10, during its last trading session.
Skechers USA Inc, declared that it has won an important ruling over Nike, Inc.’s wholly-owned partner Converse Inc. relating to the Converse Chuck Taylor shoe.
In October 2014, Converse sued Skechers in federal district court and before the International Trade Commission (“ITC”) alleging that the Company’s famous Twinkle Toes and BOBS product lines infringed its Chuck Taylor midsole common law and registered trademarks. The case went to trial before the ITC in August 2015.
In a November 17, 2015 opinion, the Chief Administrative Law Judge of the ITC, the Honorable Charles E. Bullock, ruled that Skechers’ Twinkle Toes and BOBS product lines do not infringe Converse’s registered trademark for the Chuck Taylor midsole. In making his ruling, the Judge noted that both of the Skechers product lines feature prominent branding and that the Twinkle Toes line contains design features that “create enough differences that the shoes bearing them cannot be said to be similar to [the Chuck Taylor].” The Judge also stated that the survey evidence concluded that there was no likelihood that consumers would confuse the Skechers designs with those of Converse’s Chuck Taylor designs.
Skechers U.S.A., Inc. designs, develops, markets, and distributes footwear for men, women, and children, in addition to performance footwear for men and women under the Skechers GO brand name worldwide.
Finally, Shares of Arrowhead Research Corp (NASDAQ:ARWR), ended its last trade with 5.01% gain, and closed at $6.08.
Arrowhead Research Corporation (ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, presented data from a Phase 2a clinical study at The AASLD Liver Meeting 2015® demonstrating that ARC-520, its lead drug candidate against chronic hepatitis B infection (HBV), effectively reduced HBV viral antigens derived from cccDNA. HBV surface antigen (HBsAg) was reduced substantially with a maximum reduction of 1.9 logs (99%) and a mean maximum reduction of 1.5 logs (96.8%) in treatment naïve e-antigen (HBeAg)-positive patients. This direct antiviral effect was still evident 57 days after a single dose. These data strongly support advancement of ARC-520, and Arrowhead has initiated multiple studies aimed at producing a functional cure of HBV.
Christopher Anzalone, Ph.D., Arrowhead’s president and chief executive officer said, “At AASLD we presented data from our clinical program and from a nonclinical study in chimpanzees. Both of these studies show that ARC-520 can produce deep and durable knockdown of HBV viral antigens. These data give us additional confidence in the program as we move forward with multiple-dose and combination studies of ARC-520, that we hope will lead to host immune reconstitution, HBsAg seroclearance, and functional cure.”
Arrowhead Research Corporation develops novel drugs to treat intractable diseases in the United States. The company’s principal product candidates comprise ARC-520, an RNAi-based therapeutic that is in Phase IIa clinical trial to treat chronic hepatitis B virus infection; and ARC-AAT, a novel unlocked nucleobase analog containing RNAi-based therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency.